SB-328437

SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC50 of 4.5 nM. SB-328437 can inhibit eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4. In addition, SB-328437 can sensitize 5-FU (HY-90006) -resistant gastric cancer cells. SB-328437 can also reduce the recruitment of neutrophils to the lungs and pulmonary inflammation during acute inflammation. SB-328437 can be used in the research of inflammation-related diseases[1][2][3].

Product Specifications

CAS Number

[247580-43-4]

UNSPSC

12352005

Hazard Statement

H302, H400

Target

CCR; Thymidylate Synthase

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sb-328437.html

Purity

99.58

Solubility

DMSO : 87.5 mg/mL (ultrasonic)

Smiles

O=C(OC)[C@H](CC1=CC=C([N+]([O-])=O)C=C1)NC(C2=C3C=CC=CC3=CC=C2)=O

Molecular Formula

C21H18N2O5

Molecular Weight

378.38

Precautions

H302, H400

References & Citations

[1]White JR, et al. Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. J Biol Chem. 2000 Nov 24;275 (47) :36626-31. |[2]Gutiérrez Á, et al. Targeting CCR3 with antagonist SB 328437 sensitizes 5‑fluorouracil‑resistant gastric cancer cells: Experimental evidence and computational insights. Oncol Lett. 2024 May 1;28 (1) :296.|[3]Lopez-Leal F, et al. Blockade of the CCR3 receptor reduces neutrophil recruitment to the lung during acute inflammation. J Leukoc Biol. 2024 Nov 4;116 (5) :1198-1207.